Compugen to Join Prominent Healthcare Conference
Compugen Ltd. (Nasdaq: CGEN), renowned for its innovative strategies in cancer immunotherapy and computational target discovery, is set to engage in a fireside chat during the forthcoming Stifel 2024 Healthcare Conference. This engaging discussion will take place on a day when industry leaders congregate to share insights and advancements in healthcare.
Event Details
The Compugen management team will participate in a unique fireside chat designed for an in-depth exploration of their recent developments and future directions in cancer treatment. The event is scheduled for a morning slot, allowing for seminars and networking to occur later in the day.
About Compugen and Its Innovations
Compugen stands at the forefront of clinical-stage therapeutic discovery, leveraging a compelling predictive computational discovery platform. This platform empowers the company to identify pioneering drug targets and crucial biological pathways integral to developing cutting-edge cancer immunotherapies.
Current Product Development
At present, Compugen has two proprietary product candidates progressing through Phase 1 development. The first, COM701, aims to be a first-in-class anti-PVRIG antibody, while the second, COM902, aspires to claim the title of a best-in-class antibody targeting TIGIT for solid tumor treatments. Adding to their promising pipeline, Rilvegostomig, a bispecific antibody targeting both PD-1 and TIGIT, is under development by AstraZeneca, backed by a licensing agreement. This collaboration showcases Compugen's commitment to advancing combination therapies in cancer treatment.
Addressing Immune Resistance
Compugen is not only focused on individual therapies but also on addressing various immune resistance mechanisms. Their array of early-stage immuno-oncology programs includes the advanced candidate COM503, an anti-IL-18 binding protein antibody. COM503 has received Investigational New Drug (IND) clearance from the FDA, highlighting its potential in revolutionizing cancer therapy.
Company Headquarters and Presence
Headquartered in Israel, Compugen also operates an office situated in San Francisco, California, emphasizing its commitment to global outreach in healthcare innovation. The company’s dedication to pioneering advancements resonates throughout its community of investors and stakeholders.
Company Contact Information
For inquiries, individuals may reach out to Yvonne Naughton, Ph.D., who serves as the VP, Head of Investor Relations, and Corporate Communications. The team is readily available to provide insights on the company's initiatives and future prospects.
Frequently Asked Questions
What is Compugen's main focus?
Compugen primarily focuses on clinical-stage therapeutic discovery, particularly in the field of cancer immunotherapy.
When will Compugen participate in the Stifel 2024 Healthcare Conference?
Compugen management will participate in a fireside chat at the conference, scheduled for an upcoming date.
What are Compugen's key product candidates?
Compugen's significant candidates include COM701 and COM902, targeting critical pathways in cancer immunotherapy.
Where is Compugen headquartered?
Compugen is headquartered in Israel, with additional offices located in San Francisco, California.
Who can I contact for more information about Compugen?
Yvonne Naughton, Ph.D., the VP of Investor Relations, is the contact person for further information regarding Compugen.
